Karyopharm Therapeutics Inc. (KPTI)
NASDAQ: KPTI · Real-Time Price · USD
0.598
-0.012 (-1.90%)
At close: Feb 21, 2025, 4:00 PM
0.609
+0.011 (1.77%)
After-hours: Feb 21, 2025, 5:20 PM EST
Karyopharm Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Revenue | 145.24 | 146.03 | 157.07 | 209.82 | 108.09 | |
| Revenue Growth (YoY) | -0.55% | -7.03% | -25.14% | 94.12% | 164.31% | |
| Cost of Revenue | 6.01 | 4.94 | 5.21 | 3.4 | 2.71 | |
| Gross Profit | 139.23 | 141.09 | 151.86 | 206.42 | 105.38 | |
| Selling, General & Admin | 115.44 | 131.88 | 145.4 | 143.85 | 126.42 | |
| Research & Development | 143.23 | 138.75 | 148.66 | 160.84 | 150.81 | |
| Operating Expenses | 258.67 | 270.63 | 294.06 | 304.69 | 277.23 | |
| Operating Income | -119.44 | -129.54 | -142.2 | -98.27 | -171.85 | |
| Interest Expense | -37.42 | -23.82 | -25 | -26.05 | -27.14 | |
| Interest & Investment Income | 7.4 | 10.94 | 2.36 | 0.58 | 2.82 | |
| Other Non Operating Income (Expenses) | 28.4 | -0.36 | -0.08 | -0.09 | 0.21 | |
| EBT Excluding Unusual Items | -121.07 | -142.78 | -164.92 | -123.82 | -195.96 | |
| Other Unusual Items | 44.7 | - | - | - | - | |
| Pretax Income | -76.37 | -142.78 | -164.92 | -123.82 | -195.96 | |
| Income Tax Expense | 0.06 | 0.32 | 0.37 | 0.27 | 0.31 | |
| Net Income | -76.42 | -143.1 | -165.29 | -124.09 | -196.27 | |
| Net Income to Common | -76.42 | -143.1 | -165.29 | -124.09 | -196.27 | |
| Shares Outstanding (Basic) | 122 | 114 | 82 | 75 | 72 | |
| Shares Outstanding (Diluted) | 127 | 114 | 82 | 75 | 72 | |
| Shares Change (YoY) | 11.02% | 39.51% | 8.84% | 4.41% | 16.28% | |
| EPS (Basic) | -0.63 | -1.25 | -2.02 | -1.65 | -2.72 | |
| EPS (Diluted) | -0.93 | -1.25 | -2.02 | -1.65 | -2.72 | |
| Free Cash Flow | -127.63 | -92.72 | -149.67 | -107.33 | -160.38 | |
| Free Cash Flow Per Share | -1.01 | -0.81 | -1.83 | -1.43 | -2.23 | |
| Gross Margin | 95.86% | 96.62% | 96.68% | 98.38% | 97.50% | |
| Operating Margin | -82.24% | -88.71% | -90.53% | -46.84% | -159.00% | |
| Profit Margin | -52.62% | -97.99% | -105.23% | -59.14% | -181.59% | |
| Free Cash Flow Margin | -87.88% | -63.49% | -95.29% | -51.15% | -148.38% | |
| EBITDA | -119.1 | -129.01 | -141.58 | -97.48 | -170.88 | |
| EBITDA Margin | -82.01% | -88.34% | -90.14% | -46.46% | -158.10% | |
| D&A For EBITDA | 0.34 | 0.53 | 0.62 | 0.79 | 0.97 | |
| EBIT | -119.44 | -129.54 | -142.2 | -98.27 | -171.85 | |
| EBIT Margin | -82.24% | -88.71% | -90.53% | -46.84% | -159.00% | |
| Revenue as Reported | 145.24 | 146.03 | 157.07 | 209.82 | 108.09 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.